RISK FOR GOUT IN PATIENTS WITH TYPE 2 DIABETES PRESCRIBED SODIUM GLUCOSE COTRANSPORTER 2 INHIBITORS

A study done at Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, and Sinai Health System and University of Toronto, Toronto, Ontario, Canada published in the Annals of Internal Medicine (January 14, 2020, ISSN: 003-4819) assessed the risk of gout in 295,907 adult patients with type 2 diabetes mellitus prescribed sodium-glucose cotransporter-2 inhibitors (SGLT2) and those prescribed a glucagon-like peptide-1 (GLP1) receptor antagonist.

 

Adults with type 2 diabetes prescribed a SLGT2 inhibitor may reduce their risk for gout more than those prescribed a GLP1 agonist. The study was funded by Brigham and Women's Hospital. 

 

Leonard A. Levy, DPM, MPH, Fort Lauderdale, FL

Courtesy of Barry Block, editor of PM News